nelfinavir + indinavir + efavirenz

This is a three-drug combination of the antiretroviral agents nelfinavir, indinavir, and efavirenz. All three are antiretroviral drugs used primarily in the treatment of HIV-1 infection. Nelfinavir and indinavir are protease inhibitors, while efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI). This combination was explored to optimize viral suppression through distinct mechanisms of action working synergistically to target different steps of the HIV lifecycle. There is evidence from clinical studies that combining these drugs affects their pharmacokinetics and exposures, particularly with interactions involving CYP3A4 and CYP2C19 enzymes, requiring close monitoring and possible dose adjustments[1][6][7].